Long-Term Effect of TEV-48574 in Ulcerative Colitis or Crohn's Disease

Study Title
A 24-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerative Colitis or Crohn's Disease who completed the main phase of the Dose-Ranging Study (RELIEVE UCCD LTE)
Teva Identifier
TV48574-IMM-20038
ClinicalTrials.gov Identifier
NCT05668013
Study Status
Recruiting
Trial Condition(s)
Crohn's Disease Colitis, Ulcerative
Interventions
Drug: TEV-48574
EudraCT Number
2022-002593-89

Study Description

The primary objective of the study is to evaluate the efficacy and dose response of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 2 weeks (Q2W) in adult participants with inflammatory bowel disease (IBD) Secondary objectives of the study are to evaluate the efficacy and dose response of 2 different maintenance dose regimens of TEV-48574 sc administered Q2W in adult participants with IBD to evaluate the safety and tolerability of 2 different dose regimens of TEV-48574 sc administered Q2W in adult participants with IBD, and to evaluate the immunogenicity of 2 different dose regimens of TEV-48574 sc administered Q2W in adult participants with IBD The total duration of participant participation in the study is planned to be 26 weeks for each individual participant. The study duration is approximately 30 months..

Print

Click for participation criteria and map of study locations

EudraCT Link


Key Participation Requirements

Gender
Female, Male
Age Range
Adult
Trial Duration
January 11, 2023 - March 08, 2031
Phase
Phase 3

Study Type

Interventional